After decades of research, Vertex Pharmaceuticals now has an approved pain medication. Can one of the world’s most powerful ...

As the father of an 18-year-old girl who died from a single OxyContin pill in 2006 and as a creditor in the Purdue Pharma bankruptcy proceeding, I must voice my strong disappointment in Illinois ...

Trey Kaufman-Renn wasn't the Purdue player in first-half foul trouble, and it allowed him to play a starring role. Braden Smith showcased his generosity in a first half that was explosive.

That leads he – and his two brothers – to acquire Purdue Pharmaceuticals in the early 1950s. It had been going since the 1890s, and was a relatively small player, but Arthur & Co clearly had ...

WEST LAFAYETTE − Purdue basketball's defense got it through a tough road trip to the Pacific Northwest. The Boilermakers saw their seven-game winning streak end because the offense couldn't ...

It enhances the academic, cultural and social development of the entire Purdue community. Providing cultural education through the arts is the principal objective of the Black Cultural Center’s ...

a special speaker for songs like “Hail Purdue!” Our STEM-focused urban campus is preparing students for the jobs of tomorrow in areas such as AI, biomedical engineering, data science, cybersecurity ...

Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

M, consensus $284.9M Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions. Monitor your stock picks and ...

Biogen posted strong Q4 results, surpassing estimates, while forecasting a 2025 revenue decline. The company secured up to ...

For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti ...

Vanda Pharmaceuticals sees strong growth with Fanapt for bipolar I disorder, projects 2025 revenue up 6%-26%, and targets $1B by 2030.